AU2001251311B2 - Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof - Google Patents
Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof Download PDFInfo
- Publication number
- AU2001251311B2 AU2001251311B2 AU2001251311A AU2001251311A AU2001251311B2 AU 2001251311 B2 AU2001251311 B2 AU 2001251311B2 AU 2001251311 A AU2001251311 A AU 2001251311A AU 2001251311 A AU2001251311 A AU 2001251311A AU 2001251311 B2 AU2001251311 B2 AU 2001251311B2
- Authority
- AU
- Australia
- Prior art keywords
- duct
- epithelial cells
- cells
- miillerian
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 57
- 210000000318 mullerian duct Anatomy 0.000 title claims description 9
- 238000002955 isolation Methods 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 239
- 210000001519 tissue Anatomy 0.000 claims description 92
- 235000015097 nutrients Nutrition 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 23
- 230000002163 immunogen Effects 0.000 claims description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 238000004166 bioassay Methods 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 9
- 102100035071 Vimentin Human genes 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 8
- 238000013334 tissue model Methods 0.000 claims description 8
- 108010065472 Vimentin Proteins 0.000 claims description 7
- 238000002659 cell therapy Methods 0.000 claims description 7
- 210000005048 vimentin Anatomy 0.000 claims description 7
- 108010039627 Aprotinin Proteins 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000004338 Transferrin Human genes 0.000 claims description 6
- 108090000901 Transferrin Proteins 0.000 claims description 6
- 229960004405 aprotinin Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 239000004017 serum-free culture medium Substances 0.000 claims description 6
- 239000012581 transferrin Substances 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 5
- 108010076876 Keratins Proteins 0.000 claims description 5
- 108091005461 Nucleic proteins Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 2
- 108010066302 Keratin-19 Proteins 0.000 claims description 2
- 239000002458 cell surface marker Substances 0.000 claims 3
- 241000557626 Corvus corax Species 0.000 claims 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 claims 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 claims 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 claims 1
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 claims 1
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 claims 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims 1
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 claims 1
- 101710194922 Keratin, type II cytoskeletal 1 Proteins 0.000 claims 1
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 claims 1
- 108010065070 Keratin-13 Proteins 0.000 claims 1
- 108010066330 Keratin-15 Proteins 0.000 claims 1
- 108010066364 Keratin-16 Proteins 0.000 claims 1
- 108010066327 Keratin-18 Proteins 0.000 claims 1
- 102000005706 Keratin-6 Human genes 0.000 claims 1
- 108010070557 Keratin-6 Proteins 0.000 claims 1
- 108010070507 Keratin-7 Proteins 0.000 claims 1
- 108010070511 Keratin-8 Proteins 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 238000011170 pharmaceutical development Methods 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 7
- 239000002609 medium Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 238000010186 staining Methods 0.000 description 15
- 210000003101 oviduct Anatomy 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 210000001755 duct epithelial cell Anatomy 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000003636 conditioned culture medium Substances 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 7
- 201000010881 cervical cancer Diseases 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 210000001215 vagina Anatomy 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108700005087 Homeobox Genes Proteins 0.000 description 5
- -1 Sigma) Substances 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000004696 endometrium Anatomy 0.000 description 5
- 229940126864 fibroblast growth factor Drugs 0.000 description 5
- 230000002710 gonadal effect Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101150033506 HOX gene Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 230000009786 epithelial differentiation Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001531 micro-dissection Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010083586 anti-Mullerian hormone receptor Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000002783 mesonephros Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000021062 nutrient metabolism Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 108091005706 peripheral membrane proteins Proteins 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000002965 wolffian duct Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000012736 Zonula Occludens Proteins Human genes 0.000 description 1
- 108010079485 Zonula Occludens Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940077150 progesterone and estrogen Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/545,435 | 2000-04-07 | ||
| US09/545,435 US6416999B1 (en) | 2000-04-07 | 2000-04-07 | Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
| PCT/US2001/010998 WO2001077298A2 (en) | 2000-04-07 | 2001-04-04 | Human müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001251311A1 AU2001251311A1 (en) | 2002-01-10 |
| AU2001251311B2 true AU2001251311B2 (en) | 2005-03-03 |
Family
ID=24176236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001251311A Ceased AU2001251311B2 (en) | 2000-04-07 | 2001-04-04 | Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof |
| AU5131101A Pending AU5131101A (en) | 2000-04-07 | 2001-04-04 | Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU5131101A Pending AU5131101A (en) | 2000-04-07 | 2001-04-04 | Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6416999B1 (enExample) |
| EP (1) | EP1276850B1 (enExample) |
| JP (1) | JP4748700B2 (enExample) |
| KR (1) | KR100748039B1 (enExample) |
| CN (1) | CN1423692A (enExample) |
| AT (1) | ATE398671T1 (enExample) |
| AU (2) | AU2001251311B2 (enExample) |
| CA (1) | CA2404634A1 (enExample) |
| DE (1) | DE60134469D1 (enExample) |
| DK (1) | DK1276850T3 (enExample) |
| WO (1) | WO2001077298A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416999B1 (en) * | 2000-04-07 | 2002-07-09 | Raven Biotechnologies, Inc. | Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
| WO2003068938A2 (en) * | 2002-02-12 | 2003-08-21 | Raven Biotechnologies, Inc | Human fetal bladder-derived epithelial cells |
| CA2486548A1 (en) * | 2002-05-30 | 2003-12-11 | Raven Biotechnologies, Inc. | Animal model for toxicology and dose prediction |
| EP1565489B1 (en) | 2002-06-19 | 2010-11-17 | Raven Biotechnologies, Inc. | Internalizing antibodies specific for the RAAG10 cell surface target |
| EP1581096A4 (en) * | 2002-11-13 | 2006-06-21 | Raven Biotechnologies Inc | ANTIGEN PIPA AND BINDING ANTIBODIES THEREOF |
| AP2949A (en) | 2006-03-07 | 2014-07-31 | Shroff Geeta | Compositions comprising human embryonic stem cellsand their derivatives, methods of use, and method s of preparation |
| CN101855339A (zh) * | 2007-01-22 | 2010-10-06 | 雷文生物技术公司 | 人类癌症干细胞 |
| JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| CN102732479B (zh) * | 2011-03-31 | 2014-08-27 | 北京大学 | 胸腺上皮前体细胞的制备方法及其专用培养基 |
| AU2013248265B2 (en) * | 2012-11-08 | 2018-11-01 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
| CN108061804B (zh) * | 2016-11-09 | 2020-05-12 | 北京大学人民医院 | 用于诊断子宫内膜异位症的生物标志物 |
| CN107475369B (zh) * | 2017-07-07 | 2021-05-04 | 南方医科大学 | Hoxa9基因在制备治疗皮肤鳞状细胞癌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69623109T2 (de) * | 1996-04-19 | 2002-12-12 | Societe Des Produits Nestle S.A., Vevey | Menschliche immortalisierte Colon-Epithelialzellen |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| US6416999B1 (en) * | 2000-04-07 | 2002-07-09 | Raven Biotechnologies, Inc. | Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
-
2000
- 2000-04-07 US US09/545,435 patent/US6416999B1/en not_active Expired - Fee Related
-
2001
- 2001-04-04 DE DE60134469T patent/DE60134469D1/de not_active Expired - Lifetime
- 2001-04-04 JP JP2001575152A patent/JP4748700B2/ja not_active Expired - Fee Related
- 2001-04-04 CN CN01808098A patent/CN1423692A/zh active Pending
- 2001-04-04 KR KR1020027013431A patent/KR100748039B1/ko not_active Expired - Fee Related
- 2001-04-04 AU AU2001251311A patent/AU2001251311B2/en not_active Ceased
- 2001-04-04 CA CA002404634A patent/CA2404634A1/en not_active Abandoned
- 2001-04-04 DK DK01924679T patent/DK1276850T3/da active
- 2001-04-04 AT AT01924679T patent/ATE398671T1/de not_active IP Right Cessation
- 2001-04-04 WO PCT/US2001/010998 patent/WO2001077298A2/en not_active Ceased
- 2001-04-04 EP EP01924679A patent/EP1276850B1/en not_active Expired - Lifetime
- 2001-04-04 AU AU5131101A patent/AU5131101A/xx active Pending
-
2002
- 2002-04-05 US US10/117,895 patent/US7125713B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1276850A2 (en) | 2003-01-22 |
| EP1276850B1 (en) | 2008-06-18 |
| CN1423692A (zh) | 2003-06-11 |
| WO2001077298A2 (en) | 2001-10-18 |
| DE60134469D1 (de) | 2008-07-31 |
| CA2404634A1 (en) | 2001-10-18 |
| WO2001077298A3 (en) | 2002-07-04 |
| DK1276850T3 (da) | 2008-10-13 |
| KR100748039B1 (ko) | 2007-08-09 |
| KR20030032933A (ko) | 2003-04-26 |
| JP4748700B2 (ja) | 2011-08-17 |
| US20030040110A1 (en) | 2003-02-27 |
| US7125713B2 (en) | 2006-10-24 |
| AU5131101A (en) | 2001-10-23 |
| ATE398671T1 (de) | 2008-07-15 |
| US6416999B1 (en) | 2002-07-09 |
| JP2003530100A (ja) | 2003-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2404313C (en) | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof | |
| US8021876B2 (en) | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof | |
| AU2001257597A1 (en) | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof | |
| AU2001251311B2 (en) | Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof | |
| AU2001251311A1 (en) | Human Mullerian duct-derived epithelial cells and methods of isolation and uses thereof | |
| AU2003219764B2 (en) | Human fetal bladder-derived epithelial cells | |
| AU2001253343B2 (en) | Human ovarian mesothelial cells and methods of isolation and uses thereof | |
| AU2001253343A1 (en) | Human ovarian mesothelial cells and methods of isolation and uses thereof | |
| HK1050710B (en) | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |